Wonderfully detailed post. Regarding the issue of injection patterns, since Revance is unable to advise on anything but frown lines, are there mechanisms in place where knowledgeable injectors share information with each other?
One problem is there are injectors out there right now that are dosing the same as Botox and charging the same as Botox. Reps need to do a better job to stop this.The end result will no doubt be patients unhappy with Daxxy because they are not getting the advertised duration. Injectors need better training, and an incentive from RVNC.
I hope I made the bull case for both the patient and provider in switching to Daxxify. I don't believe a lot of the analysts have truly worked the numbers to see the cost/benefit analysis in a clear way. This will become abundantly clear as new injectors gain confidence in their injection patterns and amounts as they follow up with their patients over the first 6 months, manage client expectations, and price it per unit as Revance recommends.
Very very wrong timing...you made this post right when RVNC was about to fall off the cliff.. Well Done
News 
Market Data 
Discover 
AI
